Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD

Current Medical Research and Opinion
K SaylorMichael Greenbaum

Abstract

This study measured the effects of atomoxetine HCl on high-risk behaviors and health-related quality of life in adolescents with attention-deficit/hyperactivity disorder (ADHD), using a subgroup analysis of data from a previous clinical trial. In the base study, which was conducted at 26 sites in the United States, patients ages 13-16 years were randomized in a double-blind manner to atomoxetine treatment by one of two dose titration schedules for 8 weeks. Patients who responded to treatment were rerandomized to atomoxetine at a daily dose of 0.8 or 1.4 mg/kg for 40 weeks. Patients in the highest-risk quartile for each category of behavior or domain were included and the dosing groups combined. Efficacy measures included the Youth Risk Behavior Surveillance (YRBS) and Child Health and Illness Profile - Adolescent Edition (CHIP-AE). The YRBS has six categories of behavior, and the CHIP-AE has six domains. Data for mean change from baseline were analyzed using a last-observation-carried-forward analysis. A total of 267 patients were randomized, but the high-risk subgroup analyzed in the present study was much smaller (range of n = 5-68 per group). YRBS scores for tobacco use, unhealthful dietary behaviors, inadequate physical act...Continue Reading

References

Jan 1, 1995·Journal of Substance Abuse·O F PomerleauC S Pomerleau
Dec 28, 1999·New Directions for Mental Health Services·M B Monroe-DeVita, D F Mohatt
Feb 29, 2000·Journal of Clinical Child Psychology·J W Maedgen, C L Carlson
Aug 8, 2002·Journal of the International Neuropsychological Society : JINS·Russell A BarkleyTracie Bush
Jan 28, 2003·Biological Psychiatry·David MichelsonDenái Milton
Aug 20, 2003·Journal of Consulting and Clinical Psychology·Julie Sarno Owens, Betsy Hoza
Dec 8, 2004·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Shelby L CormanColieen M Culley
May 25, 2005·Journal of Child and Adolescent Psychopharmacology·Joanne BartonSuyash Prasad
Jun 14, 2005·Journal of Occupational and Environmental Medicine·Ronald C KesslerT Bedirhan Ustün
Jun 22, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·Margaret WeissAlbert J Allen
Jan 24, 2006·Journal of the American Academy of Child and Adolescent Psychiatry·Russell A BarkleyKenneth Fletcher
Jul 13, 2006·Journal of the American Academy of Child and Adolescent Psychiatry·Gerald J AugustSusanne Lee
Sep 30, 2006·Journal of Clinical Child and Adolescent Psychology : the Official Journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53·Kate FloryBradley Smith
Apr 20, 2007·Journal of Pediatric Psychology·Amanda L ThompsonElizabeth M Gnagy
Sep 29, 2007·Clinical Child and Family Psychology Review·Julie Sarno OwensNina M Kaiser
Nov 17, 2007·The American Journal of Psychiatry·Joseph BiedermanStephen V Faraone
Jan 12, 2008·Journal of Abnormal Child Psychology·Nicole M EvangelistaWilliam E Pelham
Apr 3, 2008·The American Journal of Psychiatry·Salvatore MannuzzaFrancisco X Castellanos
Dec 29, 2009·Journal of Child and Adolescent Psychopharmacology·Linda A WietechaKory Schuh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Related Papers

Journal of the American Academy of Child and Adolescent Psychiatry
Jeffrey H NewcornAlbert J Allen
Journal of the American Academy of Child and Adolescent Psychiatry
Timothy WilensHaitao Gao
Journal of the American Academy of Child and Adolescent Psychiatry
Christopher J KratochvilATOMOXETINE HIGH-DOSE STUDY GROUP
© 2021 Meta ULC. All rights reserved